The goal of this research is to characterize the optimal manufacturing process that produces a drug containing of silver sulfadiazine (AgSD) nanoparticles that are key ingredients for various medications, particularly, ones used for skin burns. The management of difficult to heal wounds can considerably reduce the time required for tissue repairing and promote the healing process, thus minimizing the risk of infection. Silver compounds, especially silver sulfadiazine (AgSD), are often used to prevent or to treat wound bacteria colonization, even in the presence of antibiotic-resistant bacteria. The effectiveness of poorly soluble drugs, such as those applied topically to treat burns, depends on the size of the drug particle. Producing these drugs as nanoparticles significantly increases the drug solubility and effectiveness of the product. The other major factor determining the effectiveness is the concentration of nanoparticles in the product. This manufacturing method is designed to optimize the concentration of drug nanoparticles within the microemulsion system.